Quick Answer
KYNTRA BIO, INC. reported Net Income Loss of $183.45 million for the year ending 2025.
- KYNTRA BIO, INC. showed an increase of +485.6% in Net Income Loss from 2024 to 2025.
- This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$16.24 million | Q2 2014: $46.83 million | Q3 2014: -$39.54 million | Q1 2015: -$46.37 million | Q2 2015: $57.06 million | Q3 2015: -$45.10 million | Q1 2016: -$27.84 million | Q2 2016: $24.32 million | Q3 2016: -$24.15 million | Q1 2017: -$30.61 million | Q2 2017: -$31.91 million | Q3 2017: -$24.46 million | Q1 2018: -$41.40 million | Q2 2018: -$23.42 million | Q3 2018: -$42.56 million | Q1 2019: -$45.41 million | Q2 2019: $116.00 million | Q3 2019: -$49.44 million | Q1 2020: -$78.35 million | Q2 2020: -$85.31 million | Q3 2020: $33.00 million | Q1 2021: -$71.76 million | Q2 2021: -$133.99 million | Q3 2021: $49.80 million | Q1 2022: -$63.21 million | Q2 2022: -$72.62 million | Q3 2022: -$91.65 million | Q1 2023: -$76.71 million | Q2 2023: -$87.68 million | Q3 2023: -$63.62 million | Q1 2024: -$32.93 million | Q2 2024: -$15.54 million | Q3 2024: -$17.08 million | Q1 2025: $4.64 million | Q2 2025: -$7.60 million | Q3 2025: $200.64 million.
- Over the full 13 years of available data (2013 to 2025), KYNTRA BIO, INC.'s Net Income Loss has grown by 1,327.7%.
- Historical annual values: Fiscal year 2025: $183.45 million | Fiscal year 2024: -$47.58 million | Fiscal year 2023: -$284.23 million | Fiscal year 2022: -$293.65 million | Fiscal year 2021: -$290.02 million | Fiscal year 2020: -$189.29 million | Fiscal year 2019: -$76.97 million | Fiscal year 2018: -$86.42 million | Fiscal year 2017: -$120.88 million | Fiscal year 2016: -$58.07 million | Fiscal year 2015: -$85.78 million | Fiscal year 2014: -$59.50 million | Fiscal year 2013: -$14.94 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: